NUS Links:
Summary
The combination of chemotherapy (or targeted therapy) with immunotherapy is emerging rapidly as a promising strategy in the first line treatment against several tumor types. This study led by Dr Raghav Sundar provides the basis to further optimise treatment options for first-line metastatic GEAC patients using combination of Immunotherapy and chemotherapy.
Link to article: https://bit.ly/35WzvHy
Gastric cancer (GC) has significant global mortality with high heterogeneity. A study of 226 GC samples from 121 patients integrated …
The tumour microenvironment (TME) plays a pivotal role in cancer progression, metastasis, and therapeutic resistance. Comprised of diverse cells, extracellular …
Research led by N2CR member Dr. Cheok Chit Fang found that the tumour suppressor protein p53 protects DNA during replication …